Erbitux

Erbitux Indications/Uses

cetuximab

Manufacturer:

Merck

Distributor:

Zuellig Pharma
Full Prescribing Info
Indications/Uses
Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer: in combination with irinotecan-based chemotherapy, in first-line in combination with FOLFOX, as a sinle agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
For details, see Pharmacology: Pharmacodynamics under Actions.
Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck: in combination with radiation therapy for locally advanced disease, in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in